XTX301

Gilead bets on Xilio cancer drug as biotech restructures
BioPharma Dive
Thu, 03/28/24 - 11:54 am
Gilead Sciences
Xilio Therapeutics
cancer
immunotherapy
restructuring
XTX301
solid tumors